XML 45 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes In Carrying Amount Of Goodwill
Changes in the carrying amount of goodwill for the three months ended March 31, 2015 were as follows:
 
Specialty
Surgical
Solutions
 
Orthopedics and
Tissue Technologies
 
Spine
 
Total
 
(In thousands)
Goodwill, gross
$
281,829

 
$
81,650

 
$
409

 
$
363,888

Accumulated impairment losses
—

 
—

 
—

 
—

Goodwill at December 31, 2014
281,829

 
81,650

 
409

 
363,888

MicroFrance working capital and purchase price adjustments
(828
)
 
—

 
—

 
(828
)
Goodwill impairment charge
—

 
—

 
(409
)
 
(409
)
Foreign currency translation
(6,433
)
 
(2,016
)
 
—

 
(8,449
)
Balance, March 31, 2015
$
274,568

 
$
79,634

 
$
—

 
$
354,202
Components of Company's Identifiable Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 
 
March 31, 2015
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
18 years
 
$
343,942

 
$
(67,172
)
 
$
276,770

Customer relationships
12 years
 
158,546

 
(88,817
)
 
69,729

Trademarks/brand names
34 years
 
42,713

 
(15,457
)
 
27,256

Trademarks/brand names
Indefinite
 
48,484

 
—

 
48,484

Supplier relationships
27 years
 
34,721

 
(11,166
)
 
23,555

All other (1)
4 years
 
4,620

 
(2,990
)
 
1,630

 
 
 
$
633,026

 
$
(185,602
)
 
$
447,424


 
December 31, 2014
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
18 years
 
$
345,082

 
$
(62,920
)
 
$
282,162

Customer relationships
12 years
 
162,031

 
(87,653
)
 
74,378

Trademarks/brand names
34 years
 
44,520

 
(15,755
)
 
28,765

Trademarks/brand names
Indefinite
 
48,484

 
—

 
48,484

Supplier relationships
27 years
 
34,721

 
(10,809
)
 
23,912

All other (1)
4 years
 
4,810

 
(3,052
)
 
1,758

 
 
 
$
639,648

 
$
(180,189
)
 
$
459,459


 
(1) 
At March 31, 2015 and December 31, 2014, all other included in-process research and development ("IPR&D") of $1.4 million in both periods, which was indefinite-lived.